Orgenesis Inc. ORGS

ORGS Company Overview

Orgenesis Inc. (NASDAQ: ORGS) is a biotechnology and cell therapy company focused on developing and commercializing decentralized manufacturing platforms for advanced therapies, particularly cell and gene therapies. The company operates within the regenerative medicine, bioprocessing, and contract development and manufacturing organization (CDMO) industries. Orgenesis has positioned itself around enabling point-of-care and localized production models intended to reduce manufacturing complexity, lower costs, and improve accessibility for personalized therapies.

The company’s primary business activities include cell therapy processing technologies, therapeutic development support, and decentralized manufacturing infrastructure through its POCare Platform and related services. Orgenesis has historically emphasized autologous cell therapies and collaborative manufacturing networks serving biotechnology firms, hospitals, and research institutions. Founded in 2008, the company initially focused on regenerative medicine technologies and later expanded into cell and gene therapy manufacturing services, evolving toward a platform-oriented business model centered on distributed production capabilities and process standardization.